SEC Form 4 · accession 0001062993-16-012691
BIOSPECIFICS TECHNOLOGIES CORP · BSTC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Thomas Wegman
Officer — President · Director · 10% Owner
Period of report
Dec 8, 2016
Accepted (ET)
Dec 13, 2016 · 10:39 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875622
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.001 par valueF1 | Dec 8, 2016 | S | 15,000 | $49.5408 | D | 930,879 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The selling price of $49.5408 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $49.20 to $50.13. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.